Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Frankfurt - Delayed Quote EUR

Revvity, Inc. (PKN.F)

81.00
+0.14
+(0.17%)
At close: April 25 at 3:59:53 PM GMT+2

Key Executives

Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.
NameTitlePayExercisedYear Born
Dr. Prahlad R. Singh Ph.D. CEO, President & Director 3.25M 1.98M 1965
Mr. Maxwell Krakowiak Senior VP & CFO 1.01M -- 1990
Mr. Tajinder S. Vohra Senior Vice President of Global Operations 886.88k 355.26k 1966
Mr. Joel S. Goldberg Senior VP of Administration, General Counsel & Secretary 1.17M 1.03M 1969
Ms. Miriame Victor Senior VP & Chief Commercial Officer 904.24k -- 1982
Mr. Bryan A. Kipp Senior VP of Technology & Licensing -- -- --
Ms. Madhuri Hegde FACMG, Ph.D. Senior VP & Chief Scientific Officer -- -- --
Mr. Stephen Barr Willoughby Senior VP of Investor Relations & Head of ESG -- -- --
Ms. Magali Four Senior VP and Chief People & Culture Officer -- -- --
Mr. Robert Francis Friel Advisor 6.09M -- 1956

Revvity, Inc.

77 4th Avenue
Waltham, MA 02451
United States
781 663 6900 https://www.revvity.com
Sector: 
Healthcare
Full Time Employees: 
11,000

Description

Revvity, Inc. provides health sciences solutions, technologies, and services worldwide. The company's Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and DNA sequencing services. Its Diagnostics segment offers instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. It also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for use in oncology, screening newborns for rare genetic conditions, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific, BioQule, BoBs, chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPatternTM, Evolution Evoya, explorer, Fontus, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Omni Bead Ruptor, Omni Bead Ruptor Elite, Omni Tip, Pannoramic, Panthera Puncher, PG-Seq, PG-Find, PreNAT II, Prime, Protein Clear, ProteinEXact, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord, VICTOR2D, and Zephyr brands. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

Corporate Governance

Revvity, Inc.’s ISS Governance QualityScore as of April 1, 2025 is 8. The pillar scores are Audit: 9; Board: 3; Shareholder Rights: 9; Compensation: 8.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

April 28, 2025 at 12:30 PM UTC

Revvity, Inc. Earnings Date

Recent Events

April 17, 2025 at 12:00 AM UTC

Ex-Dividend Date